GlassScriptPhysician profile
Brooke S Morrow
NPI 1275670861
$3,367.19
in general payments reported to CMS, 2019-2025
22 companies · $591 in 2025
The $591 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $422 · 2022: $1,194 · 2023: $392 · 2024: $769 · 2025: $591.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,751.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,751.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $733.10 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $495.12 | 2021-2022 | |
| Lundbeck LLC | $354.83 | 2021-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $210.17 | 2022-2024 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $168.32 | 2022-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $163.88 | 2022-2025 | Spravato |
| Bausch Health US, LLC | $157.52 | 2021-2023 | Aplenzin |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $155.05 | 2022-2024 | Caplyta |
| Vanda Pharmaceuticals INC. | $151.04 | 2021-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $142.46 | 2022-2025 | Trintellix |
| Alkermes, INC. | $103.82 | 2021-2025 | Lybalvi |
| Tris Pharma INC | $89.78 | 2022-2025 | Dyanavel Xr |
| Corium, LLC | $85.69 | 2023-2025 | Azstarys |
| Collegium Pharmaceutical, INC. | $79.13 | 2025 | Jornay Pm |
| Neos Therapeutics, LP | $74.29 | 2023-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $51.79 | 2022-2024 | Quviviq |
| Ironshore Pharmaceuticals INC. | $48.84 | 2024 | |
| Neurocrine Biosciences, INC. | $26.42 | 2022 | |
| Vertical Pharmaceuticals, LLC | $22.14 | 2025 | Relexxii |
| Almatica Pharma LLC | $20.64 | 2025 | Loreev Xr |
| Noven Therapeutics, LLC | $19.00 | 2025 | Xelstrym |
| Otsuka America Pharmaceutical, INC. | $14.16 | 2024 | Abilify Mycite |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Morrow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.